H.M. BERGSTEN VENTURES

Investing in the Future of MedTech

We are a highly experienced investment firm with a dedicated focus on innovative MedTech startups. Our mission is to identify and support groundbreaking technologies with the potential to transform the healthcare industry, improve patient outcomes, and provide more effective treatments and diagnostics. By partnering with ambitious entrepreneurs and visionary researchers, we help bring disruptive medical technologies to market, ensuring that cutting-edge innovations reach the patients and healthcare professionals who need them most.

Driving Healthcare Transformation Through Technology

The healthcare landscape is evolving rapidly, with technological advancements reshaping how diseases are diagnosed, treated, and managed. We are at the forefront of this transformation, investing in companies that leverage artificial intelligence, robotics, biotechnology, and digital health solutions to enhance medical care. From advanced diagnostic tools to revolutionary treatment methods, we back MedTech pioneers who are pushing the boundaries of what is possible in medicine.

Creating Value Beyond Financial Returns

At the core of our investment philosophy is a deep commitment to creating value—not just for our investors but for people and society as a whole. We believe financial success and social impact can go hand in hand. By investing in high-potential MedTech startups, we contribute to the development of life-changing innovations that have the potential to radically improve healthcare systems worldwide.

Investing in Scalable Solutions for Medical Innovation

Every investment decision we make is guided by our mission to support businesses capable of making a real difference. We seek out startups with scalable solutions, strong leadership teams, and technologies that address pressing medical challenges. Whether it’s improving early disease detection, enabling personalized medicine, or enhancing surgical precision, we are dedicated to fostering advancements that lead to better health outcomes.

Leadership Rooted in Expertise and Vision

Our firm was founded by Mikael Bergsten, a highly accomplished investor and healthcare industry expert. As a former partner at EY (Ernst & Young) and a PhD researcher educated at Harvard Business School, Mikael brings a unique combination of financial expertise, strategic insight, and deep industry knowledge. His extensive experience in investment strategy, corporate finance, and MedTech innovation has been instrumental in shaping our approach to identifying and nurturing high-potential startups.

A Portfolio of Game-Changing MedTech Companies

Our portfolio consists of pioneering companies reshaping the medical and healthcare landscape through innovative technologies and solutions. These organizations specialize in cutting-edge developments across diagnostics, imaging, digital health, and therapeutic advancements.

• One entity in our portfolio focuses on AI-powered dermatology tools, enabling more accurate and timely skin cancer diagnoses, improving patient care, and reducing diagnostic errors.

• Another company is revolutionizing body composition analysis with MRI-based technology, providing precise insights into fat and muscle distribution to enhance healthcare decision-making.

• In the realm of oncology, our portfolio includes a company utilizing a zebrafish tumor model to accelerate drug development, ensuring faster and more reliable identification of effective cancer treatments.

• Another oncology innovator is dedicated to detecting and visualizing stem cell-like cells in brain tumors, advancing surgical precision and improving patient outcomes.

• In neurosurgery, we support an entity offering advanced optical guidance solutions that enhance surgical accuracy, reduce unnecessary interventions, and improve procedural efficiency.

• Our portfolio also includes a digital health innovator specializing in respiratory care, empowering patients with tools to monitor lung function remotely and facilitating proactive treatment.

• Additionally, we have invested in a groundbreaking approach to early cancer detection, leveraging volatile organic compounds and AI-driven analysis to enable high-sensitivity screening for ovarian cancer. This innovation holds the potential to revolutionize early-stage diagnostics and significantly improve survival rates.

By supporting these forward-thinking ventures, our portfolio drives progress in medical technology, bringing transformative solutions to healthcare providers and patients worldwide.

We Are Proud of the Work We Do

We take immense pride in the work we do and the impact we make on global health. Our investments go beyond generating returns; they are about making a lasting difference in people’s lives. From supporting breakthrough medical devices that enhance surgical precision to funding AI-driven diagnostic tools that improve early disease detection, we are actively contributing to the future of healthcare. As part of our values, we also make financial donations to the Swedish Cancer Society to support their vital work in funding cancer research in Sweden.